Replies to post #71645 on Amarin Corp Plc (AMRN)

[FishyFingers]

Amarin are simply running a large outcomes trial (SPA accepted by the FDA) to try and mirror as best they can the patient subset in JELIS that showed a 53% RRR in CVE's. R-IT has been designed and tweaked to give the best possible chance for the JELIS subset trial results to be replicated in a western population. Is that simple enough for you?

[sts66]

Huh? The Lancet isn't a peer reviewed publication?

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2960527-3/abstract

and from the Lancet's publication policy page:

For research papers, which will usually be randomised controlled trials, judged to warrant fast dissemination, The Lancet will publish a peer-reviewed manuscript within 4 weeks of receipt

Meanwhile, a google scholarly article search for "JELIS trial Lancet" gets 2,730 hits - meaning JELIS papers have been published in multiple journals, and cited in many, many more.